US seeks Biopharma rebound with new bill for domestic manufacturing hub
Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.
Lawmakers from both parties are attempting to reshape the future of biopharmaceutical manufacturing in the United States. The Biomanufacturing Excellence Act of 2025, introduced last month in both the House and Senate, proposes the creation of a national biopharmaceutical center of excellence. The initiative is designed to reduce reliance on foreign supply chains and accelerate drug production innovation.
With support from a bipartisan coalition that includes Reps. Chrissy Houlahan, Jim Baird, Deborah Ross and David Rouzer, alongside Sens. Chris Coons and Ted Budd, the legislation reflects an unusual degree of political alignment. Behind that agreement is a shared sense of urgency.
The COVID-19 pandemic, sustained geopolitical tensions with China and ongoing drug shortages have exposed the fragility of the U.S. pharmaceutical supply chain. For both policymakers and private industry, the time to rebuild domestic capacity may be narrowing.
Legislation focused on rebuilding the manufacturing base
The bill proposes the creation of a center under the National Institute of Standards and Technology to foster public and private collaboration, encourage best practices in drug production and develop the biomanufacturing workforce. The facility would allow companies to test manufacturing technologies in a compliant environment while supporting regulatory understanding of new methods.
For emerging drug developers and startups, access to a current good manufacturing practice facility could reduce commercialization risks. The center would also serve as a regulatory engagement space, enabling early dialogue between companies and federal agencies.
Supporters say the project would strengthen technical skills, improve quality standards and increase competitiveness. Lawmakers view it as part of a longer-term strategy to secure national health and economic interests.
“Biotechnology is rapidly reshaping national defense, health security and our economy’s resilience,” Rep. Rouzer said in a recent statement. “By supporting public-private collaboration and growing our domestic manufacturing base, this legislation ensures the United States can remain competitive, reduce reliance on foreign supply chains and equip the next generation of biotechnology leaders to drive our nation forward.”
The proposal follows an April report from the National Security Commission on Emerging Biotechnology, which recommended that Congress allocate $120 million to establish the center. The report warned that the U.S. could fall behind in biomanufacturing if it fails to act within the next three years.
A broader strategy to compete globally
Global competition in biotechnology is accelerating. China has invested heavily in scaling its biopharmaceutical capacity, positioning the sector as a national strategic priority. Analysts say the country has expanded both public and private support for biologics, gene therapies and active pharmaceutical ingredients.
The Biomanufacturing Excellence Act reflects a shift in U.S. policy toward greater economic security through industrial investment. It follows recent legislation aimed at similar goals, including the CHIPS and Science Act in semiconductors and the RAPID Reserve Act, which addresses drug supply chain vulnerabilities.
The Senate has also moved forward with a revised version of the Biosecure Act. The legislation targets companies with ties to Chinese firms considered a national security concern, potentially limiting their access to U.S. funding.
At the same time, the private sector is moving. A fourth-quarter report from DPR Construction shows that pharmaceutical and biotechnology companies have pledged more than $370 billion in U.S. investments for the next five years. These projects suggest that companies are already responding to geopolitical signals and policy trends.
Even with growing momentum, experts warn that establishing domestic resilience will require more than capital. According to research from Brookings and RAND, full onshoring of drug manufacturing is not always feasible. High costs, labor challenges and technical limitations remain. Many experts recommend a balanced strategy that builds domestic strength while maintaining diversified international supply lines.
Looking ahead to implementation
As the bill advances through committee, attention is shifting to execution. Industry stakeholders are watching for details about how the center would operate, who would have access, and how it would coordinate with existing federal agencies. The concept is broadly supported, but outcomes will depend on the structure, funding and governance of the initiative.
For the biotechnology industry, a national center offers the promise of reduced risk, increased speed and stronger alignment with regulatory standards. It could also provide a platform for workforce development, addressing long-standing concerns about the availability of skilled labor in advanced manufacturing.
The message from lawmakers is clear. Biopharmaceutical production is not just a technical capability but a national asset. A well-functioning, innovative and scalable drug manufacturing sector is critical not only for public health but also for economic security and strategic autonomy.
The creation of a center of excellence could mark a turning point. If successful, it would not only modernize how drugs are made but also change where and by whom they are produced. With the right alignment of public support and private investment, the United States may begin to regain ground in an industry where global leadership has become increasingly contested.